ArticleClinical ophthalmology (Auckland, N.Z.)2017
Safety of bilateral same-day intravitreal injections of anti-vascular endothelial growth factor agents.
Article in Clinical ophthalmology (Auckland, N.Z.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Endophthalmitis following same-day bilateral anti-VEGF injections: a systematic review.International ophthalmology · 2024Pooled it
- Optimizing the invisible costs of anti-VEGF: The road to regularity.Indian journal of ophthalmology · 2026Review
- Sustainability practices made easy.Eye (London, England) · 2025Review
- Safety Evaluation of Bilateral Same-Day Intravitreal Injection of Faricimab.Ophthalmology and therapy · 2025Article
- Simultaneous bilateral intravitreal anti-vascular endothelial growth factor injections from one vial for diabetic macular edema: a retrospective analysis.Frontiers in medicine · 2025Article
- Immediate sequential bilateral cataract surgery (ISBCS): A single-site experience of 41 patients during the COVID-19 pandemic.The Ulster medical journal · 2024Article
- Staphylococcus lugdunensis Endophthalmitis Following Intravitreal Anti-vascular Endothelial Growth Factor Injections.Cureus · 2022Article
- Evaluation of the Safety of Bilateral Same-Day Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents: Experience of a Large Korean Retina Center.Clinical ophthalmology (Auckland, N.Z.) · 2020Article
- Survey of Intravitreal Injection Techniques Among Retina Specialists in Mexico.Clinical ophthalmology (Auckland, N.Z.) · 2020Article
- Intravitreal Injections in Arc Sterile Setting: Safety Profile after More Than 10,000 Treatments.Journal of ophthalmology · 2020Article
- Evaluation of long-term intravitreal anti-vascular endothelial growth factor injections on renal function in patients with and without diabetic kidney disease.BMC nephrology · 2019Observational
- Current Evidence for the Prevention of Endophthalmitis in Anti-VEGF Intravitreal Injections.Journal of ophthalmology · 2018Review
- Immediate sequential bilateral intravitreal injections: an Indian perspective.Clinical ophthalmology (Auckland, N.Z.) · 2017Article
- Analyzing the Carbon Footprint of an Intravitreal Injection.Journal of ophthalmic & vision researchArticle
- Safety of simultaneous bilateral intravitreal versus unilateral anti-vasculo-endothelial growth factors injection in an operating room setting.Pakistan journal of medical sciencesArticle
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim was to evaluate the safety of bilateral same-day injections with intravitreal antiangiogenic drugs for macular diseases.
methodsCross-sectional retrospective review of unilateral and bilateral same-day antiangiogenic injections was conducted between January 2011 and March 2016 in the Unit of Macula, University and Polytechnic Hospital La Fe (Valencia, Spain). A total of 8,172 injections were administered, among which 6,560 were unilateral and 1,612 were bilateral injections. Patients were included in the study regardless of the diagnosis. Ranibizumab and aflibercept were the antiangiogenic drugs used. The presence of endophthalmitis or retinal detachment was evaluated.
resultsA total of 1 (0.012%) culture-proven endophthalmitis and 19 (0.233%) acute intraocular inflammations were registered. In the unilateral injections group, there were 18 (0.274%) acute intraocular inflammations and 1 (0.015%) culture-proven endophthalmitis. One (0.062%) of the 1,612 bilateral same-day injections had a unilateral acute intraocular inflammation, and there were no culture-proven endophthalmitis in this group.
conclusionBilateral same-day injections are more convenient for patients and their caregivers than the unilateral injections administered on different days. In our study, the prevalence of culture-proven endophthalmitis and acute intraocular inflammation was lower in the bilateral injections than in the unilateral group. These data support the idea that bilateral same-day injections are a safe and valid treatment to use in our clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.